{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:09:33Z","timestamp":1765357773807,"version":"3.33.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Inflammation is a critical protective response in the body, essential for combating infections and healing injuries. However, chronic inflammation can be harmful and significantly contribute to the development and progression of chronic diseases, with macrophage-mediated responses being central to these processes. This study presents \u201cSBR-Pel,\u201d a new therapeutic blend of Shinbaro tab (SBR), a traditional herbal formula, and pelubiprofen (Pel), a non-steroidal anti-inflammatory drug, and investigated their combined anti-inflammatory effects to create a treatment that both improves efficacy and reduces side effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>To this end, we performed both in vitro and in vivo analyses, utilizing a mouse model of inflammation. Viability and cytotoxicity assays, immunohistochemistry, enzyme-linked immunosorbent assays, real-time polymerase chain reaction assays, nociception assays, writhing tests, and blood biochemical analyses were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In vitro, SBR-Pel synergistically reduced the production of nitric oxide and reactive oxygen species and the expression of pro-inflammatory cytokines. SBR-Pel also significantly attenuated paw edema in vivo in a Complete Freund\u2019s adjuvant-induced inflammation model in adult mice. Furthermore, immunohistochemical analyses showed that treatment with SBR-Pel reduced both the infiltration of CD68<jats:sup>+<\/jats:sup> macrophages and the expression of pro-inflammatory cytokines in inflamed tissues. Additionally, compared with individual treatment alone, SBR-Pel enhanced the expression of anti-inflammatory cytokines <jats:italic>CD206<\/jats:italic>, <jats:italic>TGF-\u03b2<\/jats:italic>, and <jats:italic>IL-10<\/jats:italic>, indicating a synergistic effect. Our research demonstrates that SBR-Pel effectively diminishes inflammatory pain by reducing macrophage infiltration and pro-inflammatory cytokine secretion. Additionally, while 1.5\u00a0mg\/kg of Pel alone increases levels of liver and kidney toxicity markers, such as aspartate aminotransferase, alanine aminotransferase, and creatinine, combining it with SBR at a reduced dosage of 0.5\u00a0mg\/kg maintains these markers at normal levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This combined effect highlights SBR-Pel\u2019s potential as an effective treatment for inflammatory diseases driven by heightened macrophage activity, while also minimizing side effects by reducing the Pel dosage.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10020-025-01083-y","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:53:48Z","timestamp":1737485628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Synergistic attenuation of complete freund\u2019s adjuvant-induced inflammation in mice using shinbaro-pelubiprofen: a novel therapeutic complex"],"prefix":"10.1186","volume":"31","author":[{"given":"Hyunseong","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Young","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Jin","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhwan","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junseon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Hyuk","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"1083_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.56986\/pim.2023.02.006","volume":"2","author":"CR Ahn","year":"2023","unstructured":"Ahn CR, Jung S, Kwon S, Baek SH. In Vitro Effect of Herbal Medicines with thermal characteristics on Heat Sensitivity in Cancer cells. Perspect Integr Med. 2023;2:42\u20138.","journal-title":"Perspect Integr Med"},{"key":"1083_CR3","doi-asserted-by":"crossref","unstructured":"Austermann J, Roth J, Barczyk-Kahlert K. (2022) The Good and the Bad: Monocytes\u2019 and Macrophages\u2019 Diverse Functions in Inflammation. Cells 11.","DOI":"10.3390\/cells11121979"},{"key":"1083_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2174\/1574884711666160603012237","volume":"11","author":"G Bulaj","year":"2016","unstructured":"Bulaj G, et al. Incorporating Natural products, Pharmaceutical drugs, Self-Care and Digital\/Mobile Health Technologies into molecular-behavioral combination therapies for chronic diseases. Curr Clin Pharmacol. 2016;11:128\u201345.","journal-title":"Curr Clin Pharmacol"},{"key":"1083_CR1","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.18632\/oncotarget.23208","volume":"9","author":"L Chen","year":"2018","unstructured":"Chen L, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9:7204\u201318.","journal-title":"Oncotarget"},{"key":"1083_CR10","doi-asserted-by":"publisher","first-page":"963317","DOI":"10.3389\/fphar.2022.963317","volume":"13","author":"C Cheon","year":"2022","unstructured":"Cheon C, Ko SG. Synergistic effects of natural products in combination with anticancer agents in prostate cancer: a scoping review. Front Pharmacol. 2022;13:963317.","journal-title":"Front Pharmacol"},{"key":"1083_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/1471-2474-15-375","volume":"15","author":"IA Choi","year":"2014","unstructured":"Choi IA, et al. Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. BMC Musculoskelet Disord. 2014;15:375.","journal-title":"BMC Musculoskelet Disord"},{"key":"1083_CR22","doi-asserted-by":"crossref","unstructured":"Ding Y, Xue X. (2024) Medicinal Chemistry Strategies for the modification of Bioactive Natural products. Molecules 29.","DOI":"10.3390\/molecules29030689"},{"key":"1083_CR17","doi-asserted-by":"publisher","first-page":"e0212911","DOI":"10.1371\/journal.pone.0212911","volume":"14","author":"S Gori","year":"2019","unstructured":"Gori S, et al. Acetylcholine-treated murine dendritic cells promote inflammatory lung injury. PLoS ONE. 2019;14:e0212911.","journal-title":"PLoS ONE"},{"key":"1083_CR21","doi-asserted-by":"crossref","unstructured":"Jung Y et al. (2019) The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study. Evid Based Complement Alternat Med 2019: 2363420.","DOI":"10.1155\/2019\/2363420"},{"key":"1083_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.56986\/pim.2023.06.005","volume":"2","author":"HI Kim","year":"2023","unstructured":"Kim HI, Han Y, Park J. Bojungikgi-Tang alleviates Lipopolysaccharide-Induced inflammatory responses in RAW264.7 macrophages and C57BL\/6 mice. Perspect Integr Med. 2023;2:107\u201316.","journal-title":"Perspect Integr Med"},{"key":"1083_CR12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s12272-011-1121-0","volume":"34","author":"SY Lee","year":"2011","unstructured":"Lee SY, Kwon HK, Lee SM. SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease: first therapeutic application for the treatment of osteoarthritis. Arch Pharm Res. 2011;34:1773\u20137.","journal-title":"Arch Pharm Res"},{"key":"1083_CR2","doi-asserted-by":"crossref","unstructured":"Michels da Silva D, Langer H, Graf T. (2019) Inflammatory and molecular pathways in Heart Failure-Ischemia, HFpEF and transthyretin Cardiac Amyloidosis. Int J Mol Sci 20.","DOI":"10.3390\/ijms20092322"},{"key":"1083_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s13237-022-00405-3","volume":"65","author":"N Nasim","year":"2022","unstructured":"Nasim N, Sandeep IS, Mohanty S. Plant-derived natural products for drug discovery: current approaches and prospects. Nucleus (Calcutta). 2022;65:399\u2013411.","journal-title":"Nucleus (Calcutta)"},{"key":"1083_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.12997\/jla.2021.10.3.251","volume":"10","author":"SH Park","year":"2021","unstructured":"Park SH. Regulation of macrophage activation and differentiation in atherosclerosis. J Lipid Atheroscler. 2021;10:251\u201367.","journal-title":"J Lipid Atheroscler"},{"key":"1083_CR13","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1002\/jcb.23290","volume":"112","author":"JS Shin","year":"2011","unstructured":"Shin JS, Baek SR, Sohn SI, Cho YW, Lee KT. Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-kappaB inactivation. J Cell Biochem. 2011;112:3594\u2013603.","journal-title":"J Cell Biochem"},{"key":"1083_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","volume":"8","author":"K Solez","year":"2008","unstructured":"Solez K, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transpl. 2008;8:753\u201360.","journal-title":"Am J Transpl"},{"key":"1083_CR14","doi-asserted-by":"crossref","unstructured":"Son YJ et al. (2023) Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects. Pharmaceutics 15.","DOI":"10.3390\/pharmaceutics15041280"},{"key":"1083_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki A, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931\u20139.","journal-title":"Hepatology"},{"key":"1083_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3389\/fimmu.2019.01462","volume":"10","author":"A Viola","year":"2019","unstructured":"Viola A, Munari F, Sanchez-Rodriguez R, Scolaro T, Castegna A. The metabolic signature of macrophage responses. Front Immunol. 2019;10:1462.","journal-title":"Front Immunol"},{"key":"1083_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12950-023-00360-z","volume":"20","author":"T Xia","year":"2023","unstructured":"Xia T, et al. Advances in the study of macrophage polarization in inflammatory immune skin diseases. J Inflamm (Lond). 2023;20:33.","journal-title":"J Inflamm (Lond)"},{"key":"1083_CR11","doi-asserted-by":"crossref","unstructured":"Yang L, Wang Z. (2021) Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer. Biomedicines 9.","DOI":"10.3390\/biomedicines9060689"},{"key":"1083_CR5","doi-asserted-by":"publisher","first-page":"1080310","DOI":"10.3389\/fimmu.2023.1080310","volume":"14","author":"S Yang","year":"2023","unstructured":"Yang S, Zhao M, Jia S. Macrophage: key player in the pathogenesis of autoimmune diseases. Front Immunol. 2023;14:1080310.","journal-title":"Front Immunol"},{"key":"1083_CR15","doi-asserted-by":"publisher","first-page":"114708","DOI":"10.1016\/j.biopha.2023.114708","volume":"163","author":"YS Yoon","year":"2023","unstructured":"Yoon YS, et al. Antinociceptive and anti-inflammatory activity of DW-1021, the ionic complex of pelubiprofen and tramadol, in rodents. Biomed Pharmacother. 2023;163:114708.","journal-title":"Biomed Pharmacother"},{"key":"1083_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41232-024-00326-5","volume":"44","author":"M Yoshinaga","year":"2024","unstructured":"Yoshinaga M, Takeuchi O. Regulation of inflammatory diseases via the control of mRNA decay. Inflamm Regen. 2024;44:14.","journal-title":"Inflamm Regen"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01083-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:53:52Z","timestamp":1737485632000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01083-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01083-y","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental procedures were approved by the Jaseng Animal Care and Use Committee (Approval Number: JSR-2024-01-003-A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"AST: aspartate aminotransferase;ALT: alanine aminotransferase;BUN: blood urea nitrogen;CR: creatinine;CFA: Complete Freund\u2019s Adjuvant;CCK-8: Cell Counting Kit-8;ELISA: Enzyme-linked immunosorbent assay;H&E: hematoxylin and eosin;IL: interleukin;LPS: lipopolysaccharide;NO: nitric oxide;PBS: phosphate-buffered saline;Pel: Pelubiprofen;SBR: Shinbaro;TNF: tumor necrosis factor;","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Abbreviations"}}],"article-number":"17"}}